Alumis (ALMS) Non-Current Deferred Tax Liability (2025)

Alumis (ALMS) reported Non-Current Deferred Tax Liability of $2.1 million for Q4 2025, little changed quarter-over-quarter from $2.1 million in Q3 2025.

Alumis (ALMS) Non-Current Deferred Tax Liability (2025) Analysis & Trends

Alumis (ALMS) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $2.1 million in Q4 2025.

  • Non-Current Deferred Tax Liability for Q4 2025 came in at $2.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $2.1 million (changed N/A YoY), and the FY2025 annual result was $2.1 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability was little changed at $2.1 million in Q4 2025 per ALMS's latest filing, from $2.1 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $2.1 million in Q2 2025 and troughed at $2.1 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Alumis 1.99 Bn 1.90 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 2.14 Mn
Dec 31, 2025 2.14 Mn
Sep 30, 2025 2.14 Mn
Sep 30, 2025 2.14 Mn
Jun 30, 2025 2.14 Mn
Jun 30, 2025 2.14 Mn